

Test Offers Early Detection of Melanoma & Other Cancers

Competitive Advantages

- ☑ Diagnostic test finds over 95% of advanced melanomas.
- ☑ Extreme sensitivity allows early detection & treatment.
- ☑ Could also be used for cancers of pancreas, ovary, lung, colon & breast.
- ☑ Quantifies cancer cells; may be used to monitor effect of chemotherapy.
- ☑ Low cost to commercialize.

A new blood and tissue test can detect metastatic cancer at an early and treatable stage.

Unprecedented Sensitivity

This noninvasive test, which analyzes specific genes for abnormalities in a chemical process called DNA methylation, detects over 95% of advanced melanomas. It is also up to 1,000-fold more sensitive than other testing methods, enabling it to detect very low levels of cancer.

Improves the Prognosis

The sensitivity of the test enables patients to start treatment at an early stage of their disease, thus improving the prognosis and potentially allowing them to receive lower and less toxic doses of chemotherapy.

A Versatile Test

The test could be used for the detection of cancers other than melanoma. These include cancer of the pancreas, ovary, lung, colon, and breast.

Quantitative Measurement

Rather than detect only the presence or absence of malignant cells, the test is quantitative. It yields measurement data for metastatic cancer cells that

can be used in determining a patient's treatment and monitoring individual response to therapy.

Commercialization

We anticipate a low cost to develop and produce a commercial application of this technology. Entry into the healthcare market should be rapid as the technology does not directly involve a therapeutic intervention.

If commercialized by a medical laboratory, the test could be ordered by healthcare providers. The only specimen required would be a simple blood or tissue sample.

Next Steps

Clinical studies will determine the sensitivity and specificity of the test in patient populations.

Patent / Licensing Status

Patent pending. Exclusive rights available.

Learn More



DNA methylation video
www.uvminnovations.com/graphics/MP4s/melanoma1.mp4

Primary Investigator

Marcus Bosenberg
dermatology.yale.edu/faculty/bosenberg.html

Case Manager

Kerry Swift
 802/656-9964 (tel) 802/656-8782 (fax)
kswift@uvm.edu
 Given Building E201, Burlington, VT 05405

UVM Innovations
 The University of Vermont

Office of Technology Transfer

Biomedical / Diagnostics